Contact Us

No Form
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



   * Please describe your case:

Date of Incident : 

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Abilify Linked to Compulsive Behaviors and Gambling Lawsuit

Sep 26, 2016

Gambling Addiction Claims Linked From Abilify

Drug manufacturers Bristol-Myers Squibb and Otsuka Pharmaceuticals are facing a lawsuit from a woman alleging that the prescription drug Abilify caused her to develop a gambling addiction. The plaintiff claims that Abilify caused her to "develop compulsive gambling behaviors."

The complaint alleges that, as a result of taking Abilify, the plaintiff has "suffered and will continue to suffer neuropsychiatric and physical injury, emotional stress, harm, and economic loss." The case is pending in U.S. District Court in New Jersey.

The plaintiff began taking Abilify in September 2003, and her compulsive gambling began shortly after beginning the medication. When she stopped taking Ability in April 2014, her gambling addiction behaviors also stopped, according to the lawsuit.

Since 2002, Abilify (aripiprazole) has been prescribed to treat mental health disorders such as schizophrenia, bipolar disorder, and depression. On occasion, doctors prescribe Abilify, along with an antidepressant, for more serous depressive disorders.

Regulators Conclude Connections Of Abilify in Bahaviours

Canadian regulators concluded in November 2015 that there is "a link between the use of aripiprazole and a possible risk of pathological gambling" with the use of Abilify. This knowledge led to a warning statement for the risk of compulsive gambling being added to the prescribing information for Abilify in both Canada and Europe.

In spite of the warning in Europe and Canada, the labeling for Abilify in the United States did not sufficiently warn about the compulsive gambling risk and contained no mention that pathological gambling has been reported in patients prescribed Abilify, the lawsuit claims. The plaintiff maintains the labeling for Abilify in the United States did not contain mention of the word "gambling" until January 2016.

Need Legal Help Regarding Abilify To Gambling Behaviour

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo